Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Булгакова, В.А.; Учайкин, В. Ф.; Шамшева, О. В.; Осипова, Е. А.; Bevz, A. Yu.; Prostyakov, I. V.; Maleev, V V

doi:10.1055/s-0036-1571306

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Причем по состоянию на 2014 г. среди штаммов, циркулирующих в России, не выявлено резистентных к умифеновиру [26]. Препарат обладает низкой токсичностью, эффективен у детей в возрасте 2 лет и старше [27,28]. Как и ингибиторы нейраминидазы, умифеновир эффективен на ранних этапах развития вирусной инфекции, причем в отличие от других препаратов (ингибиторы НА и ингибиторы М 2 -каналов), даже при ошибочном назначении эффективен против других возбудителей ОРВИ [29].…”

Section: Discussionunclassified

“…Для оценки эффективности терапии по таким жестким конечным точкам, как смертность и частота развития бактериальных осложнений, ключевую роль приобретают ретроспективные исследования [35,36]. В связи с этим следует отметить, что имеющиеся данные литературы результатов ретроспективного исследования, в которых оценивалась клиническая эффективность умифеновира в течение постпандемических сезонов 2010-2011 и 2014-2015 гг., однозначно показали эффективность терапии умифеновиром, выраженную в уменьшении продолжительности как катаральных и интоксикационных синдромов, продолжительности заболевания, так и риска развития бактериальных осложнений [28,37,38].…”

Section: çàêëþ÷åíèåunclassified

See 1 more Smart Citation

Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)

Pshenichnaya

Булгакова

Львов

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

In spite of vaccination was recommended by the World Health Organization, the main strategy of influenza is antiviral drugs treatment, one of which is umifenovir. Aim. The aim of the study is to obtain additional data on safety and therapeutic efficacy of the antiviral drug Arbidol (umifenovir) in patients with a diagnosis of influenza and common cold. Materials and methods. Double-blind, randomized, placebo-controlled clinical study investigating efficacy and safety of Arbidol (umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold (ARBITR) IV phase started in November 2011 and completed in April 2016 on the basis of 15 research centers in various regions of the Russian Federation. A total of 359 patients, aged 18 to 65 years with influenza or acute respiratory tract infection, of no more than 36 hours' duration were enrolled in the study. Patients were randomized into two groups: a group of patients (therapy group) treated by Arbidol (umifenovir) at a dosage of 800 mg/day (2 capsules) for 5 days (n=181), and a group of patients receiving placebo 4 times a day for 5 days (n=178). The primary outcome measures of the study were the duration of clinical illness among patients with common cold and influenza/ARVI, the duration and severity of the main symptoms. Number of clinical complications associated with influenza and common cold was assessed as a secondary outcome. Safety was assessed by analyzing number of adverse events that are probably or definitely related to Arbidol, assessing vital signs, examining the physical condition of patients and general clinical laboratory parameters. Results. In the group treated by umifenovir, the number of full recover patients on the 4th day from the disease onset were significantly differed from the number of such cases in the placebo group. The number of cases of complete recovery after 96 hours was 98 patients (54.1%) and 77 (43.3%), p

show abstract

Section: Discussionunclassified

Section: çàêëþ÷åíèåunclassified

Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)

Pshenichnaya

Булгакова

Львов

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups

Булгакова¹,

Поромов²,

Грекова³

et al. 2017

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The FRs for influenza and ARVI complications are patient's age (children under 3 years of age and adults older than 65 years), the presence of chronic somatic diseases, and pregnancy. Patients with endocrine, eating, metabolic (including obesity), circulatory, and respiratory disorders are at high risk for influenza and ARVI complications. Umifenovir therapy substantially reduces the duration of fever and risk of complications, especially in patients with laboratory-confirmed influenza infection.

show abstract

Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years

Cited by 2 publications

References 10 publications

Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)

Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)

Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups

Contact Info

Product

Resources

About